Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03509298
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Who this might be right for
Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07830485
What this trial is testing

CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 24
Testing effectiveness (Phase 2)Looking for participantsNCT06976476
What this trial is testing

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Who this might be right for
Multiple MyelomaHypogammaglobulinemiaHypogammaglobulinemia, Acquired
Memorial Sloan Kettering Cancer Center 100
Early research (Phase 1)Study completedNCT00938626
What this trial is testing

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT01741792
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Amgen Research (Munich) GmbH 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07687004
What this trial is testing

Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)Ended earlyNCT04547101
What this trial is testing

AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumor
Akeso 6
Early research (Phase 1)Active Not RecruitingNCT04594642
What this trial is testing

AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Non Hodgkin LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma+1 more
AstraZeneca 226
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07141186
What this trial is testing

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Who this might be right for
Cervical CancerCervical Cancer MetastaticCervical Cancer Recurrent+2 more
Tianjin Medical University Cancer Institute and Hospital 50
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Looking for participantsNCT07014319
What this trial is testing

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Who this might be right for
Cytomegalovirus (CMV)
Seoul National University Hospital 20
Testing effectiveness (Phase 2)UnknownNCT06441019
What this trial is testing

Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab
Fudan University 42
Large-scale testing (Phase 3)WithdrawnNCT04563195
What this trial is testing

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Who this might be right for
Primary Sjogren's Syndrome
Matthew C. Baker
Testing effectiveness (Phase 2)Study completedNCT04785820
What this trial is testing

Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Who this might be right for
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hoffmann-La Roche 190
Testing effectiveness (Phase 2)Looking for participantsNCT06532591
What this trial is testing

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

Who this might be right for
NSCLC
Sichuan Cancer Hospital and Research Institute 20
Early research (Phase 1)Looking for participantsNCT04740424
What this trial is testing

FS222 First in Human Study in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMetastatic Cancer
invoX Pharma Limited 260
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Testing effectiveness (Phase 2)Study completedNCT04868708
What this trial is testing

AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Akeso 50
Very early researchLooking for participantsNCT07274813
What this trial is testing

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid TumorsNSCLC
Shanghai Henlius Biotech 254
Testing effectiveness (Phase 2)Looking for participantsNCT07106684
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Who this might be right for
Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China 20
Next Page